Schematic summary of the effects of ABT-737 on human oral cancer cells.... | Download Scientific Diagram
ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin–DNA adducts - ScienceDirect
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine | Journal of Molecular Signaling | Full Text
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine | Journal of Molecular Signaling | Full Text
Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review
Frontiers | BH3 Mimetics for the Treatment of Prostate Cancer | Pharmacology
Cancers | Free Full-Text | The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death | HTML
Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy - Mohana‐Kumaran - 2014 - Pigment Cell & Melanoma Research - Wiley Online Library
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT- 737 in acute myeloid leukemia - ScienceDirect
Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family members - Opferman - 2016 - The FEBS Journal - Wiley Online Library
ABT-737 - Wikipedia
Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis | Future Medicinal Chemistry
Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells | Leukemia
Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma | SpringerLink
Genetics and biomarkers in personalisation of lung cancer treatment - The Lancet
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas | PNAS
![ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2013/144/1/fig-8-2x.jpg "ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells [PeerJ]")
ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells [PeerJ]
Use of Human Cancer Cell Lines Mitochondria to Explore the Mechanisms of BH3 Peptides and ABT-737-Induced Mitochondrial Membrane Permeabilization
B Cell Lymphoma 2 and Cancer Therapy | Encyclopedia MDPI
Cancers | Free Full-Text | The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death | HTML
Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation* - Journal of Biological Chemistry
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance | Cell Death & Disease
Why do BCL-2 inhibitors work and where should we use them in the clinic? | Cell Death & Differentiation
